Table 3.

Risk of intrinsic breast cancer subtypes associated with statin use

Study populationStatin use ≥2 yearsStatin use “Never”OR (95% CI)a
Luminal A
 Controls8,889 (15.8)47,182 (84.1)Reference
 Cases931 (16.4)4,728 (83.5)1.05 (0.97–1.14)
Luminal B
 Controls1,837 (13.6)11,658 (86.4)Reference
 Cases176 (12.9)1,185 (87.1)0.96 (0.81–1.15)
HER2+/ER−
 Controls684 (12.2)4,916 (87.8)Reference
 Cases70 (12.3)498 (87.7)1.02 (0.77–1.36)
Triple negative
 Controls1,234 (12.7)8,461 (87.3)Reference
 Cases111 (11.5)851 (88.5)0.88 (0.71–1.10)
  • aORs based on conditional logistic regression among cases and their matched controls, adjusted for oral contraceptive and hormone therapy use.